These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29746307)

  • 1. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
    Gupta N; Wish JB
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
    Hörl WH
    Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities.
    Kessler C; Greindl A; Breuer B; Haberl U; Rybka A; Emgenbroich M; Frank HG; Pötgens AJ
    Cytokine; 2012 Feb; 57(2):226-37. PubMed ID: 22142701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Duration of Erythropoiesis-Stimulating Agents' Action Delays Disease Progression in Anti-Thy 1 Antibody-Induced Chronic Glomerulonephritis Rats.
    Kawasaki R; Tashiro Y; Yogo K; Serizawa K; Aizawa K; Endo K; Hirata M
    Pharmacology; 2021; 106(1-2):45-52. PubMed ID: 32829322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginesatide for the treatment of renal disease-induced anemia.
    Schmid H
    Expert Opin Pharmacother; 2013 May; 14(7):937-48. PubMed ID: 23506424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietic agents and the elderly.
    Agarwal N; Prchal JT
    Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin and erythropoiesis stimulating agents.
    Debeljak N; Sytkowski AJ
    Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease-associated anemia: new remedies.
    Del Vecchio L; Cavalli A; Tucci B; Locatelli F
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise.
    Hermanson T; Bennett CL; Macdougall IC
    Expert Opin Drug Saf; 2016 Oct; 15(10):1421-6. PubMed ID: 27551882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
    Trkulja V
    Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
    Kalantar-Zadeh K
    Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W
    Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietins: a common mechanism of action.
    Elliott S; Pham E; Macdougall IC
    Exp Hematol; 2008 Dec; 36(12):1573-84. PubMed ID: 18922615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.